We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integer (ITGR) to Co-Develop CCM Therapy with Impulse Dynamics
Read MoreHide Full Article
Leading medical device outsource manufacturer Integer Holdings Corporation (ITGR - Free Report) announced that it has signed a development agreement with Impulse Dynamics to co-develop its next-generation Lead System for Cardiac Contractility Modulation (CCM) therapy. In addition, the companies also have agreed to negotiate a supply agreement for the associated products under the development agreement.
The stock represents a negative year-to-date return of almost 44.0%, much wider than the Zacks categorized Medical Instruments sub-industry’s negative return of 2.3%.
However, we are positive about the new agreement with Impulse Dynamics. Even the markets reacted positively to the agreement and shares of Integer Holdings followed the trend. The stock rose almost 4.1% to close at $30.70 following the news release. Also, a long-term expected earnings growth rate of 15.0% and a projected sales growth of 16.4% instilled some confidence in its investors.
Meanwhile, the estimate revision trend for the stock has been mixed as one estimate moved north and one moved south in the last two months. Notably, the current year estimate for the stock stands at $2.61 per share.
Our bullishness on Integer Holdings’ focus on the CCM market is owing to the fact that it has the potential to grow rapidly. CCM is a method for treating moderate-to-severe heart failure by delivering non-excitatory electrical pulses to the heart. According to the Journal of the American College of Cardiology, heart failure is a global public health problem affecting an estimated 26 million worldwide. In the United States alone, the prevalence is 5.7 million with 670,000 new cases each year.
We believe that both the companies would benefit from the agreement. By leveraging Integer’s existing technology platform with Impulse Dynamics’ unique specifications, the duo would be able to deliver a fully customized lead solution to the CCM market 12 to 16 months earlier than developing one on their own.
Integer Holdings is a medical device outsource manufacturer. The company serves the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and power solutions markets. It also develops batteries for high-end niche applications in energy, military and environmental markets.
Zacks Rank & Key Picks
Currently, Integer Holdings has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and HMS Holdings Corp. . Addus HomeCare and LHC Group sport a Zacks Rank #1 (Strong Buy), while HMS Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of almost 43.9%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 20.5% in the last three months.
HMS Holdings has an expected earnings growth of almost 14.3%. The company posted a promising year-to-date return of almost 52.1%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Integer (ITGR) to Co-Develop CCM Therapy with Impulse Dynamics
Leading medical device outsource manufacturer Integer Holdings Corporation (ITGR - Free Report) announced that it has signed a development agreement with Impulse Dynamics to co-develop its next-generation Lead System for Cardiac Contractility Modulation (CCM) therapy. In addition, the companies also have agreed to negotiate a supply agreement for the associated products under the development agreement.
The stock represents a negative year-to-date return of almost 44.0%, much wider than the Zacks categorized Medical Instruments sub-industry’s negative return of 2.3%.
However, we are positive about the new agreement with Impulse Dynamics. Even the markets reacted positively to the agreement and shares of Integer Holdings followed the trend. The stock rose almost 4.1% to close at $30.70 following the news release. Also, a long-term expected earnings growth rate of 15.0% and a projected sales growth of 16.4% instilled some confidence in its investors.
Meanwhile, the estimate revision trend for the stock has been mixed as one estimate moved north and one moved south in the last two months. Notably, the current year estimate for the stock stands at $2.61 per share.
Our bullishness on Integer Holdings’ focus on the CCM market is owing to the fact that it has the potential to grow rapidly. CCM is a method for treating moderate-to-severe heart failure by delivering non-excitatory electrical pulses to the heart. According to the Journal of the American College of Cardiology, heart failure is a global public health problem affecting an estimated 26 million worldwide. In the United States alone, the prevalence is 5.7 million with 670,000 new cases each year.
We believe that both the companies would benefit from the agreement. By leveraging Integer’s existing technology platform with Impulse Dynamics’ unique specifications, the duo would be able to deliver a fully customized lead solution to the CCM market 12 to 16 months earlier than developing one on their own.
Integer Holdings is a medical device outsource manufacturer. The company serves the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and power solutions markets. It also develops batteries for high-end niche applications in energy, military and environmental markets.
Zacks Rank & Key Picks
Currently, Integer Holdings has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and HMS Holdings Corp. . Addus HomeCare and LHC Group sport a Zacks Rank #1 (Strong Buy), while HMS Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of almost 43.9%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 20.5% in the last three months.
HMS Holdings has an expected earnings growth of almost 14.3%. The company posted a promising year-to-date return of almost 52.1%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>